CAS: 51044-13-4; (4-Bromobenzyl)Triphenylphosphonium Bromide

上下游产品

1-bromomethyl-4-bromobenzene triphenylphosphine para-bromotoluene 4-bromobenzenemethanol 4-(3-Ethyl-1-pentyl)benzoesaeure 4-(2-n-Propyl-1-penten-1-yl)brombenzol 4-(3-Ethyl-1-heptyl)benzoesaeure 4-(2-n-Butyl-1-hexen-1-yl)brombenzol

对溴苯甲醛置于sodium Tetrahydroborate体系中,用 甲醇,乙腈 作为反应溶剂,化学反应 6.0H,反应生成 (4-溴苄基)三苯基溴化磷鎓
参考文献:新型吲哚基光敏剂与 Peg-Hec 准固态电解质结合以提高有机染料基染料敏化太阳能电池的能量转换和稳定性
标题:新型吲哚基光敏剂与 Peg-Hec 准固态电解质结合以提高有机染料基染料敏化太阳能电池的能量转换和稳定性
摘要:合成了一系列新型吲哚基有机染料,并与聚乙二醇-羟乙基纤维素准固态电解质(peg-Hec Qsse)聚合物混合碘电解质偶联,获得无金属染料基染料-具有更好稳定性的敏化太阳能电池(dssc).新合成的有机染料通过1 H,13C NMR,Chn分析.使用紫外-可见光谱法和循环伏安法技术测定染料的光学和电化学性质.通过场发射扫描电子显微镜 (Fe-Sem),紫外-可见光谱,Xrd 和 Dsc 表征了准固态 (Qss) 共混聚合物 Peg-Hec 与碘化物氧化还原对作为电解质.对具有新合成的有机染料(dpc,Dtc,Dpcy,Dtcy,Dptcy 和 Dttcy)与 Qsse 的 Dssc 设备进行了最重要的比较研究.讨论了与 Peg-Hec Qsse 偶联的所有六种染料的电化学阻抗谱,其中 Dttcy 敏化器件表现出非常好的离子电导率(1.13 x 10-3 S Cm-1),高化学电容(c µ=17
DOI:10.1016/j.Electacta.2021.138771

专利信息

专利号:US-8846910-B2
优先权日:2006-08-22
标题:Matrix metalloproteinase inhibitors
发明人：SATTIGERI VISWAJANANI J; PALLE VENKATA P; KHERA MANOJ KUMAR; REDDY RANADHEER; TIWARI MANOJ KUMAR; SONI AJAY; RAUF ABDUL REHMAN ABDUL; JOSEPH SONY; MUSIB ARPITA; DASTIDAR SUNANDA G; SRIVASTAVA PUNIT KUMAR
权利人:RANBAXY LAB LTD
摘要:The present invention relates to β-hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for their synthesis, and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune, and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase.